At the end of the latest market close, I-Mab (IMAB) was valued at $57.98. In that particular session, Stock kicked-off at the price of $61.61 while reaching the peak value of $62.525 and lowest value recorded on the day was $57.2601. The stock current value is $53.85.
Recently in News on February 9, 2021, Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced. A registered follow-on public offering by certain pre-IPO shareholders (the “Selling Shareholders”) of 3,283,950 American depositary shares (the “ADSs” and such offering, the “ADS Offering”) of I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, has priced on February 8, 2021 at a public offering price of US$54.0 per ADS. The underwriters in the ADS Offering will have a 30-day option to purchase up to 492,590 additional ADSs from certain Selling Shareholders. Each ten (10) ADSs represent twenty-three (23) ordinary shares of the Company. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
I-Mab had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $65.55 on 02/03/21, with the lowest value was $44.93 for the same time period, recorded on 01/04/21.
I-Mab (IMAB) full year performance was 427.09%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, I-Mab shares are logging -17.85% during the 52-week period from high price, and 410.43% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $10.55 and $65.55.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 808391 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the I-Mab (IMAB) recorded performance in the market was 22.97%, having the revenues showcasing 58.37% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.14B, as it employees total of 185 workers.
I-Mab (IMAB) in the eye of market guru’s
During the last month, 0 analysts gave the I-Mab a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 43.28, with a change in the price was noted +16.81. In a similar fashion, I-Mab posted a movement of +45.67% for the period of last 100 days, recording 256,904 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for IMAB is recording 0.04 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.04.
I-Mab (IMAB): Stocks Technical analysis and Trends
Raw Stochastic average of I-Mab in the period of last 50 days is set at 58.60%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 32.25%. In the last 20 days, the company’s Stochastic %K was 56.39% and its Stochastic %D was recorded 71.45%.
If we look into the earlier routines of I-Mab, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 22.97%. Additionally, trading for the stock in the period of the last six months notably improved by 92.75%, alongside a boost of 427.09% for the period of the last 12 months. The shares increased approximately by -1.34% in the 7-day charts and went down by 7.27% in the period of the last 30 days. Common stock shares were driven by 58.37% during last recorded quarter.